J&J reserves right to renegotiate Crucell buy; Amgen wins NICE nod after cutting Nplate cost;

@FiercePharma: Merck to ring in 2011 with Frazier as CEO. Article | Follow @FiercePharma

> Johnson & Johnson left open the possibility of renegotiating the 1.75-billion-euro ($2.3 billion) acquisition of Crucell should the Dutch vaccine maker's manufacturing woes worsen. News

> Amgen's platelet-boosting drug Nplate has been recommended by Britain's health cost watchdog for some patients with chronic idiopathic thrombocytopenic purpura (ITP) after the company cut its price. Report

> Bristol-Myers Squibb and Otsuka Pharmaceutical's Abilify drug won the preliminary backing of the U.K.'s health-cost agency for use in treating schizophrenia in people from 15 to 17 years old. Item

> The acne drug Accutane has been under attack for many years because of safety concerns, but in an updated position statement, the American Academy of Dermatology defends the availability of the drug and says the reports of serious side effects are not supported. Article

> A judge's ruling in an investor lawsuit over Wyeth's antidepressant Pristiq cautions that drugmakers can't rely on boilerplate cautionary language about investment risk as a defense if they don't publicize negative data on their drugs. Report

> Teva Pharmaceutical Industries will buy back as much as $1 billion in shares and American depositary receipts over the next 12 months. Story

> People who take a class of older anti-depressant drugs have an increased risk of heart disease, scientists said on Wednesday, but the risk is not increased with newer selective serotonin reuptake inhibitors (SSRI). News

> Biotech upstart touts biomarker effect in PhI ALS study. News

> Quintiles, LGL pair to offer pharmacogenetics solutions. Report 

> Marker points to new approach to treating Alzheimer's. Article

Biotech News

 @FierceBiotech: Blockbuster antibodies now face quick onslaught of biosimilars. Article | Follow @FierceBiotech

 @JohnCFierce: In a PwC survey, the FDA gets a better grade for guidance but gets an 'F' on the review process. Story | Follow @JohnCFierce

> Moore stepping down as Stem Cell Therapeutics CEO. Report

> Biotech upstart touts biomarker effect in PhI ALS study. News 

> Seattle Genetics angling for the lead in combo cancer drug race. Story 

> Histogen mounts comeback with $10M venture round. Report 

Drug Delivery News

> Good news, bad news for Impax. Story

> Problem: Getting pets to pop their pills. Article 

> South African researchers examine TB drug delivery. Item

> Ovarian cancer treatment expands in tumor. Story

> Nanoparticles created with on-off switch for cancer drugs. Report 

Medical Device News

> St. Jude, DOJ may be close to resolving kickback dispute. Report

> Experts predict advent of USB drives for medical diagnoses. Story

> Light Sciences CEO steps down as company awaits results. Item

> Micell enrolls first patient in MiStent trial. News

> SuperSonic raises $45M for imaging tech. Article

And Finally... For the second time in two months, a federal judge has upheld the constitutionality of the new healthcare law, ruling on Tuesday that the requirement that most Americans obtain medical coverage falls within Congress's authority to regulate interstate commerce. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.